Compounds > ranolazine
Page last updated: 2024-08-24

ranolazine and propranolol

ranolazine has been researched along with propranolol in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Bui-Xuan, B; Chevalier, P; Dehina, L; Descotes, J; Dizerens, N; Mamou, Z; Romestaing, C; Timour, Q1
Djamgoz, MBA; Fraser, SP; Lee, A1

Reviews

1 review(s) available for ranolazine and propranolol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for ranolazine and propranolol

ArticleYear
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Protective effects of ranolazine and propranolol, alone or combined, on the structural and functional alterations of cardiomyocyte mitochondria in a pig model of ischemia/reperfusion.
    Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:3

    Topics: Acetanilides; Animals; Calcium; Cardiotonic Agents; Disease Models, Animal; Drug Therapy, Combination; Heart Rate; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen Consumption; Piperazines; Propranolol; Ranolazine; Reactive Oxygen Species; Sus scrofa

2014
Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine.
    Journal of cellular physiology, 2019, Volume: 234, Issue:12

    Topics: Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Laminin; NAV1.5 Voltage-Gated Sodium Channel; Neoplasm Invasiveness; Potassium Channels, Voltage-Gated; Propranolol; Proteoglycans; Ranolazine; Receptors, Adrenergic, beta; Triple Negative Breast Neoplasms; Tumor Hypoxia

2019